What amount sold does Mnemosyne Pharmaceuticals Inc report in Form D filings?

The latest linked filings report $12.3M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Mnemosyne Pharmaceuticals Inc's most recent SEC filing?

Mnemosyne Pharmaceuticals Inc's most recent Form D filing was on 2015-02-04.

How many investors does Mnemosyne Pharmaceuticals Inc have?

The most recent Form D filing lists 6 investor(s).

What type of securities does Mnemosyne Pharmaceuticals Inc offer?

Mnemosyne Pharmaceuticals Inc's SEC Form D filings indicate equity offerings.

Mnemosyne Pharmaceuticals Inc

CIK: 0001542171·Biotechnology·PROVIDENCE, RI·Corporation·Founded 2010

Reported Sold

$12,332,334

Total Filings

Identified Offerings

Last Filed

Feb 4, 2015

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Feb 4, 2015Form D/A — Amendment

Reported sold: $12,332,334 · Target: $12,952,680

Rule 506(b)·6 investors

Changed: Reported amount sold, Offering target, Reported investors, Exemptions

Jul 3, 2013Form D/A — Amendment

Reported sold: $8,384,496 · Target: $11,384,496

Rule 506·6 investors

Changed: Reported amount sold, Offering target, Reported investors

Feb 1, 2013Form D/A — Amendment

Reported sold: $3,234,496 · Target: $5,384,496

Rule 506·4 investors

Feb 16, 2012Form D — New notice

Reported sold: $3,234,496 · Target: $5,384,496

Rule 506·4 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

75%

Latest reported sold across 1 identified offering

$12,332,334

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

James Bristol

Related Person

Appears on 3 filings

Frank Menniti

Related Person

Appears on 3 filings

Richard Horan

Related Person

Appears on 3 filings

Kollol Pal

Related Person

Appears on 2 filings

Peter Barrett

Related Person

Appears on 2 filings

William Koster

Related Person

Appears on 2 filings

Vanessa King

Related Person

Appears on 1 filing

Benjamin Bronstein

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Feb 4, 2015	Amendment	$12,952,680	$12,332,334	6
Jul 3, 2013	Amendment	$11,384,496	$8,384,496	6
Feb 1, 2013	Amendment	$5,384,496	$3,234,496	4
Feb 16, 2012	New	$5,384,496	$3,234,496	4

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

28bio, Inc.

Biotechnology

Offering target: $8,524,945

Filed Oct 29, 2026